Literature DB >> 6238674

Krestin (PSK).

S Tsukagoshi, Y Hashimoto, G Fujii, H Kobayashi, K Nomoto, K Orita.   

Abstract

A polysaccharide preparation isolated from Coriolus versicolor (Fr.) Quél. of Basidiomycetes (PSK) predominantly consists of glucan and approximately 25% tightly bound protein. PSK was effective against various allogeneic and syngeneic animal tumors and has been given orally to cancer patients. Various suppressed or enhanced immune responses of tumor-bearing animals were restored to normal levels by the administration of PSK in the tumor models tested. The killer T cell activity was augmented in tumor-bearing mice by intraperitoneal or oral administration of PSK, and there was correlation between the PSK associated antitumor effect and the killer T cell activity. It was found that PSK competed with immunosuppressive substances isolated from tumor-bearing mice and that the intestinal immune system appeared to be modulated by oral administration of PSK. After oral administration of 14C- or 35S-labeled PSK to normal rats, it was found that small or large molecular substances appeared in the serum depending on the time elapsed after administration, an indication that large molecular size products were from the digestive tract.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238674     DOI: 10.1016/0305-7372(84)90005-7

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  42 in total

1.  Antimicrobial activity induction by PSK subfractions: dependence on molecular weight.

Authors:  H Harada; H Sakagami; K Konno; T Sato; N Osawa; M Fujimaki; N Komatsu
Journal:  Infection       Date:  1989 Jan-Feb       Impact factor: 3.553

2.  Hericium erinaceus (Bull.: Fr.) Pers., a medicinal mushroom, activates peripheral nerve regeneration.

Authors:  Kah-Hui Wong; Gowri Kanagasabapathy; Murali Naidu; Pamela David; Vikineswary Sabaratnam
Journal:  Chin J Integr Med       Date:  2014-08-26       Impact factor: 1.978

3.  Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer.

Authors:  M Torisu; Y Hayashi; T Ishimitsu; T Fujimura; K Iwasaki; M Katano; H Yamamoto; Y Kimura; M Takesue; M Kondo
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Anti-tumour components of the culture filtrates from Tricholoma sp.

Authors:  F Liu; V E Ooi; S T Chang
Journal:  World J Microbiol Biotechnol       Date:  1995-09       Impact factor: 3.312

5.  Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy.

Authors:  T Hattori; T Nakajima; H Nakazato; T Tanabe; K Kikuchi; O Abe; T Kondo; T Taguchi; N Komi; K Sugimachi
Journal:  Jpn J Surg       Date:  1990-03

6.  Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.

Authors:  H Zhang; T Morisaki; H Matsunaga; N Sato; A Uchiyama; K Hashizume; F Nagumo; J Tadano; M Katano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

7.  beta-Glucan oligosaccharide enhances CD8(+) T cells immune response induced by a DNA vaccine encoding hepatitis B virus core antigen.

Authors:  Jing Wang; Shengfu Dong; Chunhong Liu; Wei Wang; Shuhui Sun; Jianxin Gu; Yuan Wang; Diana Boraschi; Di Qu
Journal:  J Biomed Biotechnol       Date:  2010-06-10

Review 8.  Immunomodulatory dietary polysaccharides: a systematic review of the literature.

Authors:  Jane E Ramberg; Erika D Nelson; Robert A Sinnott
Journal:  Nutr J       Date:  2010-11-18       Impact factor: 3.271

9.  Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K.

Authors:  E Yefenof; E Einat; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Immunostimulation-Mediated Anti-tumor Activity of Bamboo (Sasa senanensis) Leaf Extracts Obtained Under 'Vigorous' Condition.

Authors:  Takahiro Seki; Kenji Kida; Hiroshi Maeda
Journal:  Evid Based Complement Alternat Med       Date:  2008-05-07       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.